Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – What’s Next?

Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s share price gapped up prior to trading on Friday . The stock had previously closed at $3.34, but opened at $3.49. Esperion Therapeutics shares last traded at $3.54, with a volume of 1,088,653 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ESPR shares. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Tuesday, December 3rd. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Needham & Company LLC reduced their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Esperion Therapeutics Trading Up 4.2 %

The company has a 50 day simple moving average of $2.29 and a 200 day simple moving average of $2.20. The stock has a market capitalization of $685.70 million, a PE ratio of -5.44 and a beta of 1.01.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after acquiring an additional 3,688,796 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Esperion Therapeutics by 45.3% during the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 11,658 shares in the last quarter. Capital Advisors Wealth Management LLC lifted its holdings in shares of Esperion Therapeutics by 22.9% in the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 5,000 shares during the period. Baader Bank Aktiengesellschaft purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at approximately $132,000. Finally, Bank of New York Mellon Corp grew its holdings in Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after acquiring an additional 555,382 shares during the period. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.